Highlight Therapeutics SL Raises $15M for Clinical-Stage Immuno-Oncology

Highlight Therapeutics SL, a private, clinical-stage company, has raised $15,000,000 in a recent funding round. This investment will support the company's ongoing mission to advance its immuno-oncology initiatives, particularly the development of its lead therapeutic candidate. Formerly known as Bioncotech Therapeutics S.L, Highlight Therapeutics is dedicated to unlocking the full potential of immuno-oncology. Its primary drug candidate, BO-112, is an RNA-based therapy designed to initiate a powerful immune response. This innovative approach leverages a multi-target mechanism to transform 'cold' tumors into 'hot' tumors, making them visible and susceptible to the body's immune system. BO-112 holds potential for patients who have shown resistance to existing checkpoint inhibitor therapies. The company is currently investigating BO-112 in a range of clinical trials, both as a monotherapy and in combination with checkpoint inhibitors. Highlight Therapeutics also maintains a network of external collaborators, including prominent institutions such as Merck & Co and UCLA, further expanding its research and development efforts in the field. This secured capital is poised to be instrumental in accelerating the clinical development of BO-112, allowing the company to progress its trials and potentially expand its research capabilities. The funding round underscores investor confidence in Highlight Therapeutics' innovative scientific platform and its potential to address significant unmet medical needs within oncology. Looking ahead, Highlight Therapeutics plans to utilize this investment to continue its trajectory as a leader in immuno-oncology. The company remains focused on advancing its pipeline and bringing potentially life-changing therapies to patients, driving further growth and innovation in the fight against cancer.